C5 Inhibition Allows Continued Antineoplastic Therapy in Cancer- and Chemotherapy-associated Thrombotic Microangiopathy

Overview

Journal Blood Adv

Specialty Hematology

Date 2022 Aug 1

PMID 35914225

Authors

Hridaya Shah

Hang Chen

Xiang-Zuo Pan

Ara Metjian

Robert A Brodsky

Evan M Braunstein

Shruti Chaturvedi

Affiliations

Soon will be listed here.

Citing Articles

Peering into the darkness of drug-induced thrombotic microangiopathy: complement, are you in there?.

Sabulski A, Jodele S J Gastrointest Oncol. 2023; 14(1):468-471.

PMID: 36915433 PMC: 10007918. DOI: 10.21037/jgo-2022-04.

References

Izzedine H, Perazella M . Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015; 66(5):857-68. DOI: 10.1053/j.ajkd.2015.02.340. View

Weitz I . Thrombotic Microangiopathy in Cancer. Semin Thromb Hemost. 2019; 45(4):348-353. DOI: 10.1055/s-0039-1687893. View

Chaturvedi S, Braunstein E, Yuan X, Yu J, Alexander A, Chen H . Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2019; 135(4):239-251. PMC: 6978159. DOI: 10.1182/blood.2019003863. View

Jodele S, Zhang K, Zou F, Laskin B, Dandoy C, Myers K . The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2015; 127(8):989-96. PMC: 4828073. DOI: 10.1182/blood-2015-08-663435. View

Lechner K, Obermeier H . Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012; 91(4):195-205. DOI: 10.1097/MD.0b013e3182603598. View

Morton J, George J . Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. J Oncol Pract. 2016; 12(6):523-30. DOI: 10.1200/JOP.2016.012096. View

Jodele S, Licht C, Goebel J, Dixon B, Zhang K, Sivakumaran T . Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013; 122(12):2003-7. PMC: 3790943. DOI: 10.1182/blood-2013-05-501445. View

Eremina V, Jefferson J, Kowalewska J, Hochster H, Haas M, Weisstuch J . VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358(11):1129-36. PMC: 3030578. DOI: 10.1056/NEJMoa0707330. View

George J, Nester C . Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371(7):654-66. DOI: 10.1056/NEJMra1312353. View

10.

Blake-Haskins J, Lechleider R, Kreitman R . Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011; 17(18):5858-66. PMC: 3176977. DOI: 10.1158/1078-0432.CCR-11-0804. View

11.

Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein E . Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv. 2021; 5(5):1504-1512. PMC: 7948299. DOI: 10.1182/bloodadvances.2020003175. View

12.

Jodele S, Davies S, Lane A, Khoury J, Dandoy C, Goebel J . Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014; 124(4):645-53. PMC: 4110664. DOI: 10.1182/blood-2014-03-564997. View

13.

Rodriguez de Cordoba S, Subias Hidalgo M, Pinto S, Tortajada A . Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 2014; 40(4):422-30. DOI: 10.1055/s-0034-1375296. View

14.

Martin Merinero H, Zhang Y, Arjona E, Del Angel G, Goodfellow R, Gomez-Rubio E . Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification. Blood. 2021; 138(22):2185-2201. PMC: 8641096. DOI: 10.1182/blood.2021012037. View

15.

Weitz I, DeLoughery T . Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients. Br J Haematol. 2017; 183(1):136-139. DOI: 10.1111/bjh.14910. View

16.

Rassner M, Baur R, Wasch R, Schiffer M, Schneider J, Mackensen A . Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrol. 2021; 22(1):32. PMC: 7814610. DOI: 10.1186/s12882-020-02226-5. View

17.

Gore E, Jones B, Marques M . Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?. J Clin Apher. 2009; 24(5):209-14. DOI: 10.1002/jca.20213. View